CD147和EGFR蛋白表达与胃癌转移和预后的关系

doi:10.3760/cma.j.issn.1673422X.2016.03.006

摘要/Abstract

摘要： 目的探讨细胞外基质金属蛋白酶诱导因子CD147和表皮生长因子受体（EGFR）的表达与胃癌临床病理特征和患者预后的关系。方法应用免疫组织化学法检测63例胃癌和40例癌旁正常组织中CD147和EGFR蛋白表达，并结合肿瘤的病理学行为和临床随访资料进行分析。结果在胃癌组织中CD147和EGFR阳性表达率分别为77.8%（49/63）和42.9%（27/63），均显著高于癌旁正常组织的25.0%和0（χ²=27.851，P=0.000；χ²=23.233，P=0.000）。在胃癌组织中，CD147和EGFR表达与肿瘤浸润深度（χ²=5.992，P=0.014；χ²=13.148，P=0.000）、TNM分期（χ²=8.481，P=0.004；χ²=14.589，P=0.000）、淋巴结转移（χ²=5.270，P=0.022；χ²=20.261，P=0.000）和患者预后（χ²=5.606，P=0.018；χ²=4.982，P=0.026）密切相关；CD147表达还与Ki-67增殖指数（χ²=10.481，P=0.001）相关。CD147与EGFR的表达呈正相关（r=0.309，P=0.014）。结论 CD147和EGFR表达与胃癌发生、转移和患者生存期密切相关，检测CD147和EGFR蛋白表达可作为判断胃癌预后的参考指标。

关键词: 胃肿瘤, 预后, 抗原, CD147, 表皮生长因子

Abstract: Objective To investigate the expressions of extracellular matrix metalloproteinase inducer molecule CD147 and epidermal growth factor receptor (EGFR) protein in gastric cancer and their relationship with the pathological behavior and prognosis. Methods Immunohistochemical staining was used to detect the expressions of CD147 and EGFR protein in 63 cases of gastric cancer and 40 cases of paracancerous normal tissues. The study was also combined with analysis of the pathological behavior and clinical follow-up survey of gastric cancer. Results The positive expression rates of CD147 and EGFR protein in gastric cancer were 77.8%（49/63） and 42.9%（27/63）, respectively, which were higher than those in paracancerous normal tissues 25.0% and 0 （χ²=27.851， P=0.000； χ²=23.233， P=0.000）. In gastric cancer, the expressions of CD147 and EGFR were closely related to the depth invasion （χ²=5.992， P=0.014； χ²13.148， P=0.000）, TNM stages （χ²=8.481， P=0.004； χ²=14.589， P=0.000）, lymph node metastasis （χ²=5.270， P=0.022； χ²=20.261， P=0.000） and prognosis of patients （χ²5.606，P=0.018； χ²=4.982， P=0.026）. The expression of CD147 was also significantly correlated with Ki-67 expression （χ²=10.481， P=0.001）. CD147 expression was positively correlated with EGFR expression（r=0.309， P=0.014）. Conclusion The expressions of CD147 and EGFR are closely related to carcinogenesis, metastasis and survival time of gastric cancer. Detecting the expressions of CD147 and EGFR may be prognostic indicators of gastric cancer.

Key words: Stomach neoplasms, Prognosis, Antigens, CD147, Epidermal growth factor

周萍,付勇,高文华,卢宁. CD147和EGFR蛋白表达与胃癌转移和预后的关系[J]. 国际肿瘤学杂志, 2016, 43(3): 184-187.

Zhou Ping, Fu Yong, Gao Wenhua, Lu Ning. Expressions of CD147 and EGFR protein and their relationship with metastasis and prognosis of gastric cancer[J]. Journal of International Oncology, 2016, 43(3): 184-187.

参考文献

［1］周明星, 肖何. CD147、HER-2蛋白表达与胃癌侵袭转移的关系［J］. 临床与实验病理学杂志, 2013, 29(11): 1250-1252. ［2］李刚, 顾荣民, 文旭, 等. 人表皮生长因子受体家族在胃癌中表达的临床意义［J］. 中华胃肠外科杂志, 2013, 16(7): 668-672. DOI: 10.3760/cma.j.issn.1671-0274.2013.07.019. ［3］ Yuan Y, Shen N, Yang SY, et al. Extracellular matrix metalloprotei-nase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer［J］. Oncol Lett, 2015, 10(1): 342-348. DOI: 10.3892/ol.2015.3177. ［4］ Huang L, Xu AM, Peng Q. CD147 and MMP-9 expressions in type Ⅱ/Ⅲ adenocarcinoma of esophagogastric junction and their clinicopathological significances［J］. Int J Clin Exp Pathol, 2015, 8(2): 1929-1937. ［5］ Yu YH, Morales J, Feng L, et al. CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study［J］. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(5): 553-565. DOI: 10.1016/j.oooo.2014.12.022. ［6］ Wang B, Xu YF, He BS, et al. RNAimediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensiti-vity to cisplatin in SGC7901 cells in vitro［J］. J Exp Clin Cancer Res, 2010, 29(1): 61. DOI: 10.1186/1756-9966-29-61. ［7］ Jin EH, Lee DH, Jung SA, et al. Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer［J］. World J Gastroenterol, 2015, 21(2): 571-577. DOI: 10.3748/wjg.v21.i2.571. ［8］ Tang D, Liu CY, Shen D, et al. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas［J］. Onco Targets Ther, 2015, 8: 7-14. DOI: 10.2147/OTT.S70922. ［9］ Menashi S, Serova M, Ma L, et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells［J］. Cancer Res, 2003, 63(22): 7575-7580. （收稿日期：20150512修回日期：20150624）

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[15]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.